EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$73.90 USD
+1.40 (1.94%)
Updated Sep 19, 2025 03:51 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ERFSF 73.90 +1.40(1.94%)
Will ERFSF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ERFSF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERFSF
EUROFINS SCIENT (ERFSF) Upgraded to Buy: What Does It Mean for the Stock?
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
ERFSF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
EUROFINS SCIENT (ERFSF) Upgraded to Strong Buy: Here's Why
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
Other News for ERFSF
Eurofins Scientific price target raised by EUR 2 at Morgan Stanley
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q2 2025 Update
What Worked In Q2: Longleaf's Most Impactful Global Holdings
Eurofins Scientific price target raised by EUR 8 at Berenberg
Eurofins Scientific price target raised by EUR 10.40 at Citi